<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37296153</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>09</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Asymptomatic immunodeficiency-associated vaccine-derived poliovirus infections in two UK children.</ArticleTitle><Pagination><StartPage>3413</StartPage><MedlinePgn>3413</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3413</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-39094-0</ELocationID><Abstract><AbstractText>Increasing detections of vaccine-derived poliovirus (VDPV) globally, including in countries previously declared polio free, is a public health emergency of international concern. Individuals with primary immunodeficiency (PID) can excrete polioviruses for prolonged periods, which could act as a source of cryptic transmission of viruses with potential to cause neurological disease. Here, we report on the detection of immunodeficiency-associated VDPVs (iVDPV) from two asymptomatic male PID children in the UK in 2019. The first child cleared poliovirus with increased doses of intravenous immunoglobulin, the second child following haematopoetic stem cell transplantation. We perform genetic and phenotypic characterisation of the infecting strains, demonstrating intra-host evolution and a neurovirulent phenotype in transgenic mice. Our findings highlight a pressing need to strengthen polio surveillance. Systematic collection of stool from asymptomatic PID patients who are at high risk for poliovirus excretion could improve the ability to detect and contain iVDPVs.</AbstractText><CopyrightInformation>Â© 2023. Crown.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singanayagam</LastName><ForeName>Anika</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2572-0173</Identifier><AffiliationInfo><Affiliation>Polio Reference Service, UK Health Security Agency, Colindale, London, UK. anika.singanayagam@ukhsa.gov.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK. anika.singanayagam@ukhsa.gov.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klapsa</LastName><ForeName>Dimitra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burton-Fanning</LastName><ForeName>Shirelle</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Microbiology and Virology Services, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hand</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Polio Reference Service, UK Health Security Agency, Colindale, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilton</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stephens</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mate</LastName><ForeName>Ryan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shillitoe</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4407-5998</Identifier><AffiliationInfo><Affiliation>Paediatric Stem Cell Transplant Unit, Great North Children's Hospital, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sheffield Children's NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celma</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2223-5057</Identifier><AffiliationInfo><Affiliation>Polio Reference Service, UK Health Security Agency, Colindale, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slatter</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Paediatric Stem Cell Transplant Unit, Great North Children's Hospital, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flood</LastName><ForeName>Terry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Paediatric Stem Cell Transplant Unit, Great North Children's Hospital, Newcastle upon Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gopal</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Polio Reference Service, UK Health Security Agency, Colindale, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5326-7081</Identifier><AffiliationInfo><Affiliation>Division of Vaccines, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Potters Bar, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zambon</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Polio Reference Service, UK Health Security Agency, Colindale, London, UK. maria.zambon@ukhsa.gov.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007153" MajorTopicYN="Y">Immunologic Deficiency Syndromes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>15</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>9</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37296153</ArticleId><ArticleId IdType="pmc">PMC10251316</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-39094-0</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-39094-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organisation (WHO). Statement of the thirty third Polio IHR Emergency Committee. https://www.who.int/news/item/01-11-2022-statement-of-the-thirty-third-polio-ihr-emergency-committee (2022).</Citation></Reference><Reference><Citation>Klapsa, D. et al. Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance. Lancet. https://linkinghub.elsevier.com/retrieve/pii/S0140673622018049 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9627700</ArticleId><ArticleId IdType="pubmed">36243024</ArticleId></ArticleIdList></Reference><Reference><Citation>LinkâGelles R, et al. Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewaterâNew York, JuneâAugust 2022. Am. J. Transplant. 2022;22:2470â2474. doi: 10.1111/ajt.16677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16677</ArticleId><ArticleId IdType="pubmed">36196495</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation (WHO). Detection of circulating vaccine derived polio virus 2 (cVDPV2) in environmental samplesâ the United Kingdom of Great Britain and Northern Ireland and the United States of America. https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON408 (2022).</Citation></Reference><Reference><Citation>World Health Organisation (WHO). Circulating Vaccine-derived Poliovirus Type 3 â Israel (WHO, 2022).</Citation></Reference><Reference><Citation>Yao N, et al. Detection of a highly divergent type 3 vaccine-derived poliovirus in a child with a severe primary immunodeficiency disorder â Chongqing, China, 2022. Morb. Mortal. Wkly Rep. 2022;71:1148â1150. doi: 10.15585/mmwr.mm7136a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7136a2</ArticleId><ArticleId IdType="pmc">PMC9470223</ArticleId><ArticleId IdType="pubmed">36074738</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G, et al. Update on immunodeficiency-associated vaccine-derived polioviruses â worldwide, July 2018âDecember 2019. Morb. Mortal. Wkly Rep. 2020;69:913â917. doi: 10.15585/mmwr.mm6928a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6928a4</ArticleId><ArticleId IdType="pmc">PMC7366852</ArticleId><ArticleId IdType="pubmed">32673297</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin, G. et al. Prolonged excretion of poliovirus among individuals with primary immunodeficiency disorder: an analysis of the World Health Organization Registry. Front. Immunol. 8. http://journal.frontiersin.org/article/10.3389/fimmu.2017.01103/full (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01103/full</ArticleId><ArticleId IdType="pmc">PMC5622164</ArticleId><ArticleId IdType="pubmed">28993765</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaghaghi M, et al. Vaccine-derived poliovirus infection among patients with primary immunodeficiency and effect of patient screening on disease outcomes, Iran. Emerg. Infect. Dis. 2019;25:2005â2012. doi: 10.3201/eid2511.190540.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2511.190540</ArticleId><ArticleId IdType="pmc">PMC6810208</ArticleId><ArticleId IdType="pubmed">31625840</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, et al. Poliovirus excretion among persons with primary immune deficiency disorders: summary of a seven-country study series. J. Infect. Dis. 2014;210:S368âS372. doi: 10.1093/infdis/jiu065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu065</ArticleId><ArticleId IdType="pubmed">25316857</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghamohammadi, A. et al. Patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication. Front. Immunol.8. http://journal.frontiersin.org/article/10.3389/fimmu.2017.00685/full (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00685/full</ArticleId><ArticleId IdType="pmc">PMC5468416</ArticleId><ArticleId IdType="pubmed">28952612</ArticleId></ArticleIdList></Reference><Reference><Citation>Galal NM, et al. Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: cliniciansâ perspectives in the endgame plan for polio eradication. BMC Res. Notes. 2018;11:717. doi: 10.1186/s13104-018-3822-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-018-3822-7</ArticleId><ArticleId IdType="pmc">PMC6180599</ArticleId><ArticleId IdType="pubmed">30305145</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlov DN, et al. Prevalence of vaccine-derived polioviruses in stools of immunodeficient children in South Africa. J. Appl. Microbiol. 2006;101:1367â1379. doi: 10.1111/j.1365-2672.2006.03020.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2672.2006.03020.x</ArticleId><ArticleId IdType="pubmed">17105568</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty MC, et al. Poliovirus excretion in children with primary immunodeficiency disorders, India. Emerg. Infect. Dis. 2017;23:1664â1670. doi: 10.3201/eid2310.170724.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2310.170724</ArticleId><ArticleId IdType="pmc">PMC5621533</ArticleId><ArticleId IdType="pubmed">28930011</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander JP, et al. Transmission of Imported VaccineâDerived Poliovirus in an Undervaccinated Community in Minnesota. J. Infect. Dis. 2009;199:391â397. doi: 10.1086/596052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/596052</ArticleId><ArticleId IdType="pubmed">19090774</ArticleId></ArticleIdList></Reference><Reference><Citation>AvellÃ³n A, et al. Paralysis case and contact spread of recombinant vaccineâderived poliovirus, Spain. Emerg. Infect. Dis. 2008;14:1807â1809. doi: 10.3201/eid1411.080517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1411.080517</ArticleId><ArticleId IdType="pmc">PMC2630745</ArticleId><ArticleId IdType="pubmed">18976579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson AL, et al. Surveillance to track progress toward polio eradication â worldwide, 2020â2021. Morb. Mortal. Wkly Rep. 2022;71:538â544. doi: 10.15585/mmwr.mm7115a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7115a2</ArticleId><ArticleId IdType="pmc">PMC9020859</ArticleId><ArticleId IdType="pubmed">35421079</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai YA, Chen X, Kunasekaran M, Rahman B, MacIntyre CR. Global epidemiology of vaccine-derived poliovirus 2016â2021: a descriptive analysis and retrospective case-control study. eClinicalMedicine. 2022;50:101508. doi: 10.1016/j.eclinm.2022.101508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101508</ArticleId><ArticleId IdType="pmc">PMC9240990</ArticleId><ArticleId IdType="pubmed">35784443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao K, et al. Are circulating type 2 vaccine-derived polioviruses (VDPVs) genetically distinguishable from immunodeficiency-associated VDPVs? Comput. Struct. Biotechnol. J. 2017;15:456â462. doi: 10.1016/j.csbj.2017.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2017.09.004</ArticleId><ArticleId IdType="pmc">PMC5671402</ArticleId><ArticleId IdType="pubmed">29276577</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay, A. S. &amp; Zipursky, S. A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story. Lancet Infect. Dis.https://linkinghub.elsevier.com/retrieve/pii/S1473309922005825 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36162417</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Health Security Agency. Expansion of polio sewage surveillance to areas outside London. https://www.gov.uk/government/news/expansion-of-polio-sewage-surveillance-to-areas-outside-london</Citation></Reference><Reference><Citation>Pethani AS, et al. Poliovirus excretion among children with primary immune deficiency in Pakistan: a pilot surveillance study protocol. BMJ Open. 2021;11:e045904. doi: 10.1136/bmjopen-2020-045904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-045904</ArticleId><ArticleId IdType="pmc">PMC8319991</ArticleId><ArticleId IdType="pubmed">34321293</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. Global polio surveillance action plan. https://polioeradication.org/wp-content/uploads/2022/05/GPSAP-2022-2024-EN.pdf.</Citation></Reference><Reference><Citation>Shaghaghi M, et al. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. Vaccine. 2018;36:1711â1719. doi: 10.1016/j.vaccine.2018.02.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.02.059</ArticleId><ArticleId IdType="pubmed">29478755</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessaud M, Joffret M-L, Blondel B, Delpeyroux F. Exchanges of genomic domains between poliovirus and other cocirculating species C enteroviruses reveal a high degree of plasticity. Sci. Rep. 2016;6:38831. doi: 10.1038/srep38831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep38831</ArticleId><ArticleId IdType="pmc">PMC5153852</ArticleId><ArticleId IdType="pubmed">27958320</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaghaghi M, et al. Clearing vaccine-derived poliovirus infection following hematopoietic stem cell transplantation: a case report and review of literature. J. Clin. Immunol. 2018;38:610â616. doi: 10.1007/s10875-018-0521-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-018-0521-z</ArticleId><ArticleId IdType="pubmed">29948575</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLennan C, et al. Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet. 2004;363:1509â1513. doi: 10.1016/S0140-6736(04)16150-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16150-3</ArticleId><ArticleId IdType="pubmed">15135598</ArticleId></ArticleIdList></Reference><Reference><Citation>Kankam, M. K., Burns, J. M., Collett, M. S., Corrado, M. L. &amp; Hincks, J. R. A phase 1 study of the safety, tolerability, and pharmacokinetics of single and multiple oral doses of V-7404 in healthy adult volunteers. Antimicrob. Agents Chemother. 65. https://journals.asm.org/doi/10.1128/AAC.01029-21 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01029-21</ArticleId><ArticleId IdType="pmc">PMC8448163</ArticleId><ArticleId IdType="pubmed">34370575</ArticleId></ArticleIdList></Reference><Reference><Citation>Iturriza-GÃ³mara M, Megson B, Gray J. Molecular detection and characterization of human enteroviruses directly from clinical samples using RT-PCR and DNA sequencing. J. Med. Virol. 2006;78:243â253. doi: 10.1002/jmv.20533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20533</ArticleId><ArticleId IdType="pubmed">16372287</ArticleId></ArticleIdList></Reference><Reference><Citation>Nix WA, Oberste MS, Pallansch MA. Sensitive, seminested PCR amplification of VP1 sequences for direct identification of all enterovirus serotypes from original clinical specimens. J. Clin. Microbiol. 2006;44:2698â2704. doi: 10.1128/JCM.00542-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00542-06</ArticleId><ArticleId IdType="pmc">PMC1594621</ArticleId><ArticleId IdType="pubmed">16891480</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation (WHO). Polio Laboratory Manual, 4th edn (WHO, Geneva, Switzerland, 2004).</Citation></Reference><Reference><Citation>World Health Organisation (WHO). S1. Supplement to the WHO Polio Laboratory Manual. An alternative test algorithm for poliovirus isolation and characterisation. https://polioeradication.org/wp-content/uploads/2017/05/NewAlgorithmForPoliovirusIsolationSupplement1.pdf.</Citation></Reference><Reference><Citation>Global Polio Laboratory Network. Guidance paper 4. Cell authentication testing. 2018 https://polioeradication.org/wp-content/uploads/2020/01/GP4-Cell-Authentication-Testing-Vs1.pdf (2018).</Citation></Reference><Reference><Citation>Stern A, et al. The evolutionary pathway to virulence of an RNA virus. Cell. 2017;169:35â46.e19. doi: 10.1016/j.cell.2017.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.03.013</ArticleId><ArticleId IdType="pmc">PMC5787669</ArticleId><ArticleId IdType="pubmed">28340348</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar M, et al. Isolation of vaccine-like poliovirus strains in sewage samples from the United Kingdom. J. Infect. Dis. 2018;217:1222â1230. doi: 10.1093/infdis/jix667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix667</ArticleId><ArticleId IdType="pubmed">29309594</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar, M. et al. Environmental surveillance reveals complex enterovirus circulation patterns in human populations. Open Forum Infect Dis.5. https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofy250/5113366 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofy250/5113366</ArticleId><ArticleId IdType="pmc">PMC6201154</ArticleId><ArticleId IdType="pubmed">30377626</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw, A. G. et al. Rapid and sensitive direct detection and identification of poliovirus from stool and environmental surveillance samples by use of nanopore sequencing. J. Clin. Microbiol.58. https://journals.asm.org/doi/10.1128/JCM.00920-20 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00920-20</ArticleId><ArticleId IdType="pmc">PMC7448630</ArticleId><ArticleId IdType="pubmed">32611795</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura, K. &amp; Nei, M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol. Biol. Evol.https://academic.oup.com/mbe/article/10/3/512/1016366/Estimation-of-the-number-of-nucleotide (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8336541</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, S., Stecher, G., Li, M., Knyaz, C., Tamura, K. MEGA X: molecular evolutionary genetics analysis across computing platforms. Mol. Biol. Evol.35:1547â1549. https://academic.oup.com/mbe/article/35/6/1547/4990887 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5967553</ArticleId><ArticleId IdType="pubmed">29722887</ArticleId></ArticleIdList></Reference><Reference><Citation>UK Home Office. Code of practice for the housing and care of animals bred, supplied or used for scientific purposes. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/388535/CoPanimalsWeb.pdf (2014).</Citation></Reference><Reference><Citation>World Health Organisation (WHO). Neurovirulence Test of Types 1, 2 or 3 Live attenuated Poliomyelitis vaccines (Oral) in Transgenic Mice susceptible to Poliovirus (2021).</Citation></Reference><Reference><Citation>KÃ¤rber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. 1931;162:480â483. doi: 10.1007/BF01863914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01863914</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>